Segment disclosures

Company overview

Gyre Therapeutics, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

4 dimension combinations 37 retained observations 16 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Beijing Continent Pharmaceuticals Co Ltd

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=gyre:BeijingContinentPharmaceuticalsCoLtdMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31113450000 USD20240327Open filing evidence
2022-01-01 – 2022-12-31102290000 USD20240327Open filing evidence

Gyre

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=gyre:GyreMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30508000 USD20261106Open filing evidence
2026-01-01 – 2026-09-302427000 USD20261106Open filing evidence
2026-04-01 – 2026-06-308000 USD20260807Open filing evidence
2026-01-01 – 2026-06-301919000 USD20260807Open filing evidence
2026-01-01 – 2026-03-310 USD20260508Open filing evidence
2025-07-01 – 2025-09-302130000 USD20261106Open filing evidence
2025-01-01 – 2025-09-3013606000 USD20261106Open filing evidence
2025-04-01 – 2025-06-302963000 USD20260807Open filing evidence
2025-01-01 – 2025-06-3011476000 USD20260807Open filing evidence
2025-01-01 – 2025-03-310 USD20260508Open filing evidence

Gyre Pharmaceuticals

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=gyre:GyrePharmaceuticalsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3032426000 USD20261106Open filing evidence
2026-01-01 – 2026-09-3084042000 USD20261106Open filing evidence
2026-04-01 – 2026-06-3029097000 USD20260807Open filing evidence
2026-01-01 – 2026-06-3051616000 USD20260807Open filing evidence
2026-01-01 – 2026-03-3122519000 USD20260508Open filing evidence
2025-01-01 – 2025-12-31116588000 USD20260313Open filing evidence
2025-07-01 – 2025-09-3030564000 USD20261106Open filing evidence
2025-01-01 – 2025-09-3079393000 USD20261106Open filing evidence
2025-04-01 – 2025-06-3026771000 USD20260807Open filing evidence
2025-01-01 – 2025-06-3048829000 USD20260807Open filing evidence
2025-01-01 – 2025-03-3122058000 USD20260508Open filing evidence
2024-01-01 – 2024-12-31105757000 USD20260313Open filing evidence
2024-07-01 – 2024-09-3025488000 USD20251107Open filing evidence
2024-01-01 – 2024-09-3077885000 USD20251107Open filing evidence
2024-04-01 – 2024-06-3025225000 USD20250811Open filing evidence
2024-01-01 – 2024-06-3052397000 USD20250811Open filing evidence
2024-01-01 – 2024-03-3127172000 USD20250509Open filing evidence
2023-01-01 – 2023-12-31113450000 USD20250317Open filing evidence
2023-07-01 – 2023-09-3032042000 USD20241113Open filing evidence
2023-01-01 – 2023-09-3086302000 USD20241113Open filing evidence
2023-04-01 – 2023-06-3029329000 USD20240813Open filing evidence
2023-01-01 – 2023-06-3054260000 USD20240813Open filing evidence
2023-01-01 – 2023-03-3124931000 USD20240513Open filing evidence

All Other Segments

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=us-gaap:AllOtherSegmentsMember
PeriodValueUnitFiledEvidence
2026-01-01 – 2026-03-310 USD20260508Open filing evidence
2025-01-01 – 2025-03-310 USD20260508Open filing evidence